Abstract: A method of treating a female patient suffering from non-small cell lung cancer includes the step of administering to the patient in need thereof a composition of 2,2?-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof. The method can include other primary line therapies.

Abstract: Methods for determining the likelihood that a subject suffering from a solid tumor cancer will benefit from treatment with an illudin are disclosed herein. Further, there are also methods for treatment based on such determination. In several embodiments, markers prostaglandin reductase 1 (PTGR1), Protein Tyrosine Phosphatase Non-Receptor Type 14 (PTPN14), Aspartate Beta-Hydroxylase (ASPH) together with one or more genes or alone may be used to enhance or guide treatment with an illudin. In certain embodiments, the protein or gene may be expressed or methylated.